TTP-αL Inhibitors

TTP-αL Inhibitors primarily include chemicals that inhibit enzymes in the PI3K signaling pathway, such as PI3K itself, mTOR, and AKT. These inhibitors exert their effects through various mechanisms. Some, such as LY294002, Wortmannin, BKM120, PI-103, BEZ235, ZSTK474, and GDC-0941, directly inhibit PI3K, the key enzyme in the pathway that TTP-αL is involved in. The inhibition of PI3K disrupts the signaling cascade, leading to decreased functional activity of TTP-αL as a downstream effector of this signaling pathway.

Other inhibitors, including Rapamycin, AZD8055, Everolimus, and KU-0063794, target mTOR, a downstream component of the PI3K pathway. By inhibiting mTOR, these chemicals disrupt the PI3K signaling pathway, indirectly leading to decreased functional activity of TTP-αL. A-443654 is an ATP-competitive inhibitor of AKT kinases, another integral part of the PI3K pathway. By inhibiting AKT, A-443654 can disrupt the PI3K signaling pathway, leading to decreased functional activity of TTP-αL.